Skip to main content
Erschienen in:

01.05.2020 | Original Article

Serum adiponectin levels between patients with Parkinson’s disease and those with PSP

verfasst von: Hiroshi Kataoka, Kazuma Sugie

Erschienen in: Neurological Sciences | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Adiponectin receptors are expressed in the hypothalamus, brainstem, and basal ganglia. Experimentally, adiponectin was immunopositive in the phosphorylated α-synuclein-positive Lewy bodies in the brain of individuals with Parkinson’s disease (PD), and treatment with recombinant adiponectin suppressed the aggregation of α-synuclein. The close relationship between adiponectin and PD is suggested.

Methods

We assessed whether adiponectin levels may increase in patients with PD and differ in individuals with other neurodegenerative diseases. Blood samples were stored at − 70 °C. Adiponectin levels were measured using a latex turbidimetric immunoassay.

Results

Adiponectin levels of patients with PD (p = 0.019) or PD plus multiple systemic atrophy with predominant parkinsonian features (MSA-P) (p = 0.034) increased compared with those of patients with progressive supranuclear palsy (PSP). A multivariate comparison using ANCOVA showed that the adiponectin level was significantly higher in PD plus MSA-P than in patient with PSP, which is independent of age and BMI (adjusted mean difference of 4.388 μg/ml [95% confidence interval 0.602–8.174, p = 0.024]). A significant positive correlation between adiponectin and HDL-C levels was observed in patients with PD on a single linear regression analysis (β, 0.257; p < 0.001; R2 = 0.271). The results were not significant in patients with MSA-P, PSP, and MSA-P plus PSP.

Conclusions

Adiponectin is likely to play roles in the composition of lipid rafts since the adiponectin level of each patient with alpha-synucleinopathy or PSP differed.
Literatur
1.
Zurück zum Zitat Lara-Castro C, Fu Y, Chung BH, Garvey WT (2007) Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18:263–270PubMedCrossRef Lara-Castro C, Fu Y, Chung BH, Garvey WT (2007) Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18:263–270PubMedCrossRef
2.
Zurück zum Zitat Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, Lefebvre d'Hellencourt C (2016) Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research. J Neuroinflammation 13:67PubMedPubMedCentralCrossRef Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, Lefebvre d'Hellencourt C (2016) Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research. J Neuroinflammation 13:67PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK, Moskowitz MA, Ouchi N (2008) Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117:216–223PubMedCrossRef Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK, Moskowitz MA, Ouchi N (2008) Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117:216–223PubMedCrossRef
4.
Zurück zum Zitat Yang Y, Hu W, Jiang S, Wang B, Li Y, Fan C, Di S, Ma Z, Lau WB, Qu Y (2015) The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases. Biochim Biophys Acta 1852:1887–1894PubMedCrossRef Yang Y, Hu W, Jiang S, Wang B, Li Y, Fan C, Di S, Ma Z, Lau WB, Qu Y (2015) The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases. Biochim Biophys Acta 1852:1887–1894PubMedCrossRef
5.
Zurück zum Zitat Markus HS, Tomkins AM, Stern GM (1993) Increased prevalence of undernutrition in Parkinson’s disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect 5:117–125PubMedCrossRef Markus HS, Tomkins AM, Stern GM (1993) Increased prevalence of undernutrition in Parkinson’s disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect 5:117–125PubMedCrossRef
6.
Zurück zum Zitat Markus HS, Cox M, Tomkins AM (1992) Raised resting energy expenditure in Parkinson’s disease and its relationship to muscle rigidity. Clin Sci (Lond) 83:199–204CrossRef Markus HS, Cox M, Tomkins AM (1992) Raised resting energy expenditure in Parkinson’s disease and its relationship to muscle rigidity. Clin Sci (Lond) 83:199–204CrossRef
7.
Zurück zum Zitat Quan Li LY, Sun L, Yan J, Yan X, Fang L, Li M, Fan Z (2012) Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease. Metabolism 61:1803–1808PubMedCrossRef Quan Li LY, Sun L, Yan J, Yan X, Fang L, Li M, Fan Z (2012) Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease. Metabolism 61:1803–1808PubMedCrossRef
8.
Zurück zum Zitat Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184–1188PubMedCrossRef Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184–1188PubMedCrossRef
9.
Zurück zum Zitat Cassani E, Cancello R, Cavanna F, Maestrini S, Di Blasio AM, Liuzzi A, Pezzoli G, Barichella M (2011) Serum adiponectin levels in advanced-stage Parkinson’s disease patients. Parkinsons Dis 2011:624764PubMedPubMedCentral Cassani E, Cancello R, Cavanna F, Maestrini S, Di Blasio AM, Liuzzi A, Pezzoli G, Barichella M (2011) Serum adiponectin levels in advanced-stage Parkinson’s disease patients. Parkinsons Dis 2011:624764PubMedPubMedCentral
11.
Zurück zum Zitat Matsunaga E, Nambu S, Oka M, Iriki A (2013) Differential cadherin expression in the developing postnatal telencephalon of a New World monkey. J Comp Neurol 521:4027–4060PubMed Matsunaga E, Nambu S, Oka M, Iriki A (2013) Differential cadherin expression in the developing postnatal telencephalon of a New World monkey. J Comp Neurol 521:4027–4060PubMed
12.
Zurück zum Zitat Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE (2000) Alpha-synuclein membrane interactions and lipid specificity. J Biol Chem 275:34328–34334PubMedCrossRef Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE (2000) Alpha-synuclein membrane interactions and lipid specificity. J Biol Chem 275:34328–34334PubMedCrossRef
13.
Zurück zum Zitat Araki K, Yagi N, Ikemoto Y, Yagi H, Choong CJ, Hayakawa H, Beck G, Sumi H, Fujimura H, Moriwaki T, Nagai Y, Goto Y, Mochizuki H (2015) Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson’s disease patients. Sci Rep 5:17625PubMedPubMedCentralCrossRef Araki K, Yagi N, Ikemoto Y, Yagi H, Choong CJ, Hayakawa H, Beck G, Sumi H, Fujimura H, Moriwaki T, Nagai Y, Goto Y, Mochizuki H (2015) Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson’s disease patients. Sci Rep 5:17625PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Sekiyama K, Waragai M, Akatsu H, Sugama S, Takenouchi T, Takamatsu Y, Fujita M, Sekigawa A, Rockenstein E, Inoue S, La Spada AR, Masliah E, Hashimoto M (2014) Disease-modifying effect of adiponectin in model of α-synucleinopathies. Ann Clin Transl Neurol 1:479–489PubMedPubMedCentralCrossRef Sekiyama K, Waragai M, Akatsu H, Sugama S, Takenouchi T, Takamatsu Y, Fujita M, Sekigawa A, Rockenstein E, Inoue S, La Spada AR, Masliah E, Hashimoto M (2014) Disease-modifying effect of adiponectin in model of α-synucleinopathies. Ann Clin Transl Neurol 1:479–489PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Li X, Geng J, Liu J (2014) Adiponectin offers protection against L166P mutant DJ-1-induced neuronal cytotoxicity mediated by APPL1-dependent AMPK activation. Int J Neurosci 124:350–361PubMedCrossRef Li X, Geng J, Liu J (2014) Adiponectin offers protection against L166P mutant DJ-1-induced neuronal cytotoxicity mediated by APPL1-dependent AMPK activation. Int J Neurosci 124:350–361PubMedCrossRef
16.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedPubMedCentralCrossRef Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK, EMSA-SG (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25:2604–2612PubMedCrossRef Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK, EMSA-SG (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25:2604–2612PubMedCrossRef
18.
Zurück zum Zitat Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676PubMedPubMedCentralCrossRef Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, Movement Disorder Society-endorsed PSP Study Group (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864PubMedPubMedCentralCrossRef Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, Movement Disorder Society-endorsed PSP Study Group (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Marin R, Diaz M (2018) Estrogen interactions with lipid rafts related to neuroprotection impact of brain ageing and menopause. Front Neurosci 12:128PubMedPubMedCentralCrossRef Marin R, Diaz M (2018) Estrogen interactions with lipid rafts related to neuroprotection impact of brain ageing and menopause. Front Neurosci 12:128PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Fabelo N, Martín V, Santpere G, Marín R, Torrent L, Ferrer I, Díaz M (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol Med 17(9–10):1107–1118PubMedPubMedCentralCrossRef Fabelo N, Martín V, Santpere G, Marín R, Torrent L, Ferrer I, Díaz M (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol Med 17(9–10):1107–1118PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816–830PubMedCrossRef Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816–830PubMedCrossRef
23.
Zurück zum Zitat Marin R, Fabelo N, Martín V, Garcia-Esparcia P, Ferrer I, Quinto-Alemany D, Díaz M (2017) Anomalies occurring in lipid profiles and protein distribution in frontal cortex lipid rafts in dementia with Lewy bodies disclose neurochemical traits partially shared by Alzheimer’s and Parkinson’s diseases. Neurobiol Aging 49:52–59PubMedCrossRef Marin R, Fabelo N, Martín V, Garcia-Esparcia P, Ferrer I, Quinto-Alemany D, Díaz M (2017) Anomalies occurring in lipid profiles and protein distribution in frontal cortex lipid rafts in dementia with Lewy bodies disclose neurochemical traits partially shared by Alzheimer’s and Parkinson’s diseases. Neurobiol Aging 49:52–59PubMedCrossRef
24.
Zurück zum Zitat Samuel F, Flavin WP, Iqbal S, Pacelli C, Sri Renganathan SD, Trudeau LE, Campbell EM, Fraser PE, Tandon A (2016) Effects of serine 129 phosphorylation on α-synuclein aggregation, membrane association, and internalization. J Biol Chem 291:4374–4385PubMedCrossRef Samuel F, Flavin WP, Iqbal S, Pacelli C, Sri Renganathan SD, Trudeau LE, Campbell EM, Fraser PE, Tandon A (2016) Effects of serine 129 phosphorylation on α-synuclein aggregation, membrane association, and internalization. J Biol Chem 291:4374–4385PubMedCrossRef
25.
Zurück zum Zitat Wan Z, Mah D, Simtchouk S, Klegeris A, Little JP (2014) Globular adiponectin induces a pro-inflammatory response in human astrocytic cells. Biochem Biophys Res Commun 446(1):37–42PubMedCrossRef Wan Z, Mah D, Simtchouk S, Klegeris A, Little JP (2014) Globular adiponectin induces a pro-inflammatory response in human astrocytic cells. Biochem Biophys Res Commun 446(1):37–42PubMedCrossRef
26.
Zurück zum Zitat Spranger J, Verma S, Gohring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman SM, Tschöp M, Banks WA (2006) Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55:141–147PubMedCrossRef Spranger J, Verma S, Gohring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman SM, Tschöp M, Banks WA (2006) Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55:141–147PubMedCrossRef
27.
Zurück zum Zitat Diniz TA, Aquino Júnior JCJ, Mosele FC, Cabral-Santos C, Lima Junior EA, Teixeira AAS, Lira FS, Rosa Neto JC (2019) Exercise-induced AMPK activation and IL-6 muscle production are disturbed in adiponectin knockout mice. Cytokine 119:71–80PubMedCrossRef Diniz TA, Aquino Júnior JCJ, Mosele FC, Cabral-Santos C, Lima Junior EA, Teixeira AAS, Lira FS, Rosa Neto JC (2019) Exercise-induced AMPK activation and IL-6 muscle production are disturbed in adiponectin knockout mice. Cytokine 119:71–80PubMedCrossRef
29.
Zurück zum Zitat Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012) Non-motor symptoms in patients with Parkinson’s disease - correlations with inflammatory cytokines in serum. PLoS One 7:e47387PubMedPubMedCentralCrossRef Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012) Non-motor symptoms in patients with Parkinson’s disease - correlations with inflammatory cytokines in serum. PLoS One 7:e47387PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Scalzo P, Kümmer A, Cardoso F, Teixeira AL (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci Lett 468:56–58PubMedCrossRef Scalzo P, Kümmer A, Cardoso F, Teixeira AL (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci Lett 468:56–58PubMedCrossRef
31.
Zurück zum Zitat Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324PubMedCrossRef Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324PubMedCrossRef
32.
Zurück zum Zitat Nübling G, Schuberth M, Feldmer K, Giese A, Holdt LM, Teupser D, Lorenzl S (2017) Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy. Exp Brain Res 235:2407–2412PubMedCrossRef Nübling G, Schuberth M, Feldmer K, Giese A, Holdt LM, Teupser D, Lorenzl S (2017) Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy. Exp Brain Res 235:2407–2412PubMedCrossRef
33.
Zurück zum Zitat Rocha NP, Scalzo PL, Barbosa IG, de Sousa MS, Morato IB, Vieira EL, Christo PP, Reis HJ, Teixeira AL (2014) Circulating levels of adipokines in Parkinson’s disease. J Neurol Sci 339(1–2):64–68PubMedCrossRef Rocha NP, Scalzo PL, Barbosa IG, de Sousa MS, Morato IB, Vieira EL, Christo PP, Reis HJ, Teixeira AL (2014) Circulating levels of adipokines in Parkinson’s disease. J Neurol Sci 339(1–2):64–68PubMedCrossRef
34.
Zurück zum Zitat Arai Y, Takayama M, Abe Y, Hirose N (2011) Adipokines and aging. J Atheroscler Thromb 18(7):545–550PubMedCrossRef Arai Y, Takayama M, Abe Y, Hirose N (2011) Adipokines and aging. J Atheroscler Thromb 18(7):545–550PubMedCrossRef
35.
Zurück zum Zitat Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46(4):459–469PubMedCrossRef Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46(4):459–469PubMedCrossRef
36.
Zurück zum Zitat Bansal N, Charlton-Menys V, Pemberton P, McElduff P, Oldroyd J, Vyas A, Koudsi A, Clayton PE, Cruickshank JK, Durrington PN (2006) Adiponectin in umbilical cord blood is inversely related to low-density lipoprotein cholesterol but not ethnicity. J Clin Endocrinol Metab 91:2244–2249PubMedCrossRef Bansal N, Charlton-Menys V, Pemberton P, McElduff P, Oldroyd J, Vyas A, Koudsi A, Clayton PE, Cruickshank JK, Durrington PN (2006) Adiponectin in umbilical cord blood is inversely related to low-density lipoprotein cholesterol but not ethnicity. J Clin Endocrinol Metab 91:2244–2249PubMedCrossRef
37.
Zurück zum Zitat Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS (2011) Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation 124:1663–1672PubMedPubMedCentralCrossRef Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS (2011) Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation 124:1663–1672PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Zhang Y, McGillicuddy FC, Hinkle CC, O'Neill S, Glick JM, Rothblat GH, Reilly MP (2010) Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121:1347–1355PubMedPubMedCentralCrossRef Zhang Y, McGillicuddy FC, Hinkle CC, O'Neill S, Glick JM, Rothblat GH, Reilly MP (2010) Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121:1347–1355PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 289:1799–1804CrossRef Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 289:1799–1804CrossRef
40.
Zurück zum Zitat Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, Frittitta L (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89:2665–2671PubMedCrossRef Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, Frittitta L (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89:2665–2671PubMedCrossRef
41.
Zurück zum Zitat Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A (2003) Weight loss in Parkinson’s disease. Ann Neurol 53:676–679PubMedCrossRef Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A (2003) Weight loss in Parkinson’s disease. Ann Neurol 53:676–679PubMedCrossRef
42.
Zurück zum Zitat Martínez HR, Escamilla-Ocañas CE, Camara-Lemarroy CR, González-Garza MT, Tenorio-Pedraza JM, Hernández-Torre M (2017) CSF concentrations of adipsin and adiponectin in patients with amyotrophic lateral sclerosis. Acta Neurol Belg 117:879–883PubMedCrossRef Martínez HR, Escamilla-Ocañas CE, Camara-Lemarroy CR, González-Garza MT, Tenorio-Pedraza JM, Hernández-Torre M (2017) CSF concentrations of adipsin and adiponectin in patients with amyotrophic lateral sclerosis. Acta Neurol Belg 117:879–883PubMedCrossRef
43.
Zurück zum Zitat Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741PubMedCrossRef Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741PubMedCrossRef
Metadaten
Titel
Serum adiponectin levels between patients with Parkinson’s disease and those with PSP
verfasst von
Hiroshi Kataoka
Kazuma Sugie
Publikationsdatum
01.05.2020
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 5/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-019-04216-4

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Kaliumhaltiges Kochsalz schützt vor Schlaganfallrezidiven

Erhalten Menschen nach einem Schlaganfall statt normalem Kochsalz eine kaliumhaltige Alternative, reduziert dies sowohl das Risiko für erneute ischämische und hämorrhagische Insulte als auch die Gesamtmortalität. Dafür sprechen Ergebnisse einer großen randomisierten Studie.

Der Mann mit der Alzheimermutation, der keine Demenz bekommt

Nur sehr selten werden Menschen mit einer Alzheimermutation von einer familiären Demenz verschont, was meist an protektiven Genvarianten liegt. Ein über 70-jähriger Mann stellt die Forschung jedoch vor ein Rätsel. Vielleicht hat ihm die Arbeit in großer Hitze geholfen.

Auch nach TIA kommt es zu kognitivem Abbau

Trotz raschem und vollständigem Verschwinden der Symptome bergen auch transitorische ischämische Attacken das Risiko langfristigen kognitiven Abbaus, wie eine Studie zeigt. Die Größenordnung gleicht jener nach einem Schlaganfall.

Schlaganfall oder Schlaganfall-Imitator?

Ein breites Spektrum von Erkrankungen kann einen Schlaganfall vortäuschen. Bei der notwendigen schnellen Unterscheidung zwischen solchen „stroke mimics“ und echten Schlaganfällen können einige klinische Faktoren und Symptome unterstützend herangezogen werden. 

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.